This study aimed to identify FDA-approved CYP4Z1 inhibitors with anti-breast cancer activity through a drug repurposing strategy, thereby providing preclinical evidence for potential clinical adjuvant therapies. The gene discussed is CYP4Z1; the disease is breast cancer.